Overview

A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the response to treatment and safety of paliperidone extended-release (mechanism to dissolve a drug over time in order to be released slower and steadier into the blood stream) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

Phase:

Phase 4

Details

Lead Sponsor:

Janssen-Cilag Turkey

Treatments:

Paliperidone Palmitate